Avelumab plus axitinib significantly improve PFS in untreated renal cell carcinoma
Credit: © European Society for Medical Oncology Munich, Germany, 21 October 2018 - A combination of the immune checkpoint blocker, avelumab, plus the tyrosine kinase...









